

1 **Supplementary Information**

2 **Paeoniflorin relieves arterial stiffness induced by a high-fat/high-** 3 **sugar diet by disrupting the YAP-PPM1B interaction**

4

5

6 **Materials and methods**

7 **Animals**

8 Eight-week-old male C57BL/6J mice were purchased from Beijing Vital River
9 Laboratory Animal Technology (Beijing, China). All mice were maintained in SPF
10 facility conditions before experiments. All animal experiments were conducted in
11 accordance with the National Institutes of Health Guide for the Care and Use of
12 Laboratory Animals and approved by the Institutional Animal Care and Use Committee
13 of Tianjin Medical University. Mice were fed a high-fat, high-sucrose diet or a normal
14 diet.

15 **Glucose tolerance test (GTT)**

16 After 8 hours of fasting, mice were injected with 30% glucose at a dose of 2g/kg body
17 weight and then their blood glucose was measured at 0, 15, 30, 60, 90, 120 minutes
18 using a blood glucose meter.

19 **Immunoprecipitation**

20 The cells are lysed using lysate and their whole cell lysate is extracted. To quantify the
21 protein concentration using BCA, 1 mg of protein was added to 20 uL of anti-myc
22 immunomagnetic beads overnight at 4°C and then the beads were washed 5 times with
23 buffer (NaCl 136.89 mM, KCl 2.67 mM, Na₂HPO₄ 8.1 mM, KH₂PO₄ 1.76 mM, and
24 0.5% Tween20). After the last wash the supernatant was removed leaving the
25 immunomagnetic beads, which were resuspended by adding 1X SDS and then boiled
26 for 10 minutes followed by western blot analysis.

27 **Immunofluorescence staining**

28 Arterial sections were incubated in PBS buffer containing 5% goat serum, 0.1% Triton
29 X-100 for 1 hour at room temperature, followed by incubation of the primary antibody

1 corresponding to the protein overnight at 4°C, followed by two washes with PBS and
2 incubation of the secondary antibody for one hour at room temperature. The ratios of
3 antibodies used were: anti-collagen type I (1:200), anti- α -SMA (1:100), anti-YAP
4 (1:100), anti-p-Smad2^{ser465 /Ser467} (1:80), anti-PPM1B (1:80). Fluoroshield mounting
5 medium with DAPI was used to cover slides, and images were captured using a Zeiss
6 confocal laser-scanning microscope.

7 **Nanoluc Binary Technology (Nanobit)-based binding assay**

8 The LgBiT and SmBiT genes were inserted at the C-terminus of the YAP-CC domain
9 or PPM1B to obtain the lentiviral constructs encoding YAP-CC-LgBiT and PPM1B-
10 SmBiT, respectively. A stable HeLa cell line expressing both YAP-CC-LgBiT and
11 PPM1B- SmBiT was established. The cells were seeded into white 96-well cell culture
12 plates. Nano-Glo live cell reagent was added to each well and allowed to incubate for
13 10 min at 37°C, and the baseline luminescence was measured. Diluted compounds from
14 the FDA-approved drug screening library or vehicle at a final concentration of 10 μ M
15 were added, and luminescence was monitored after 1 h. The luminescence levels were
16 normalized to the baseline value, and the compounds with relative luminescence level
17 below 0.7 were selected.

18 **Vascular stiffness**

19 Aortic stiffness was assessed by measuring pulse wave velocity and circumferential
20 cyclic strain in mice using the ultra-high resolution small animal ultrasound imaging
21 system vevo2100, recording aortic pulse waves in B-mode and aortic diameter and
22 vessel wall thickness in M-mode. Systolic diameter (Ds) and diastolic diameter (Dd)
23 were recorded and circumferential cyclic strain $(D_s - D_d)/D_d$ was calculated. Pulse
24 travel time was calculated as the transit time of each waveform between the sites using
25 the R-wave of the ECG as a reference point. PWV (mm/ms) was calculated by dividing
26 the distance by transit time.

27 **Cell culture and plasmid transfection**

28 HEK293T cells and HeLa cells were cultured in DMEM medium containing 10% fetal
29 bovine serum and 1% penicillin-streptomycin solution. 0.05 mg/mL ascorbic acid; 0.01
30 mg/mL insulin; 0.01 mg/mL transferrin; 10 ng/mL sodium selenite; 0.03 mg/mL

1 endothelial cell growth supplement (ECGS); 10 mM HEPES, 10 mM TES and 10%
2 fetal bovine serum and 1% penicillin-streptomycin were added to the basal F-12
3 medium, Human aortic smooth muscle cells were then cultured in the medium.
4 HEK293T cells were grown to 70%–80% when plasmid transfection was performed
5 using TransIntro® EL Transfection Reagent.

6 **Luciferase reporter assay**

7 HASMCs cells were transfected with the Smad binding element (SBE) luciferase
8 reporter and β -galactosidase for 24 h, and then incubated with TGF- β 1 (5 ng/mL) for 6
9 h. Luciferase activities were measured using a luciferase assay system (Promega,
10 Madison, WI) and β -galactosidase was quantified using the enzyme assay system as an
11 internal control (Promega, Madison, WI).

12 **Extraction proteins and western blot analysis**

13 Animal tissue or cell lysates using RIPA lysates which contain complete protease-
14 inhibitor cocktail (Cat. No. 04693132001; Roche, Indianapolis, IN, USA), phosphatase
15 inhibitors (Cat. No. 04906845001; Roche) and PMSF (Cat. No. P0100; Solarbio Life
16 Sciences; Beijing, China). For western-blot analysis, protein samples were separated
17 by SDS-PAGE and transferred onto nitrocellulose membranes. Nitrocellulose
18 membranes are incubated with primary antibody after closure. Rabbit anti-YAP (Cat#
19 14074S), Rabbit anti-p-Smad2^(Ser465/467) (Cat# 3108), Rabbit anti-Smad2 (Cat#5339)
20 Rabbit anti-Smad3 (Cat#9523) Rabbit anti-DYKDDDDK Tag (Cat#14793) were
21 purchased from Cell Signaling Technology, Rabbit anti-p-Smad3^(Ser423/425) (Cat#
22 ab52903) and Rabbit anti-VWF (Cat# ab154193) were purchased from Abcam, Mouse
23 anti-GAPDH (Cat#60004-1-Ig) was purchased from ProteinTech, Mouse anti-
24 DYKDDDDK Tag (Cat# F1804) were purchased from Sigma-Aldrich, Rabbit Anti- α -
25 SMA (Cat#14-9760-82) was purchased from ThermoFisher. Quantification of band
26 intensity of immunoblots using ImageJ software.

27 **Surface Plasmon Resonance (SPR) experiment**

28 The interactions between peptides and proteins were investigated using the Biacore 8
29 K system (Cytiva, USA). The recombinant PPM1B protein was diluted in 10 mM
30 acetate (pH 5.0) and immobilized on a Biacore CM5 sensor chip via primary amine

1 groups. Approximately 15000 resonance units (RU) of the immobilized protein were
2 obtained. Interaction analyses were performed using HBS-P containing MgCl₂ (10 μM)
3 as a running buffer. Increasing concentrations of polypeptides (SciLight Biotechnology)
4 were passed through the chip at a flow rate of 30 μL/min, and data were analyzed using
5 Biacore evaluation software (8k Version 2.0.15), and the curve was fitted with a 1:1
6 binding model. To determine competition with the compounds, PPM1B was
7 immobilized on a CM5 sensor chip. The polypeptide (20 μM) or mixed with compound
8 (20 μM) was injected onto the chip until a binding steady state was reached.

9 **Biolayer interferometry (BLI) experiment**

10 The binding affinity of Paeoniflorin to YAP-CC was determined using the Octet Red
11 96 Molecular Interaction Analyser. The His-YAP-CC protein was coupled to the NI-
12 NTA biosensor, and for each assay, five NI-NTA biosensors were taken and placed on
13 the sensor tray and soaked in PBST buffer for 10 min. The His-YAP-CC protein was
14 diluted to 100 ug/mL with PBST protein solution, and the prepared Paeoniflorin PA was
15 diluted with PBST to form five concentration gradients, and finally the His-YAP-CC
16 protein, and the gradient diluted PA, buffer were added to the sample plate for detection.
17 A 1:1 binding model was assumed in binding kinetics analysis. KD, Kon, Koff and R2
18 values were reported.

19

20

1 **Figure S1. Paeoniflorin relieved HFHS-induced arterial stiffness by disrupting**
2 **YAP-PPM1B interaction.**

3 (A) Immunoblot analysis of Flag-YAP-CC-LgBiT and Flag-PPM1B-SmBiT protein
4 levels in stably transfected HeLa cell lines using an anti-FLAG antibody. (B) HeLa cell
5 lines stably expressing LgBiT-YAP-CC and SmBiT-PPM1B were plated in white 96-
6 well cell culture plates for 12 h, and then treated with the indicated compounds (1 μ M)
7 for 1 h before luminescence was monitored. *P*-values correspond to one-way ANOVA
8 with Bonferroni post-test ($n = 3$). (C) Plasma levels of glucose were measured after
9 intraperitoneal injection of 30% glucose to achieve a final dose of 2 mg/kg body weight
10 ($n = 5$). (D) The epididymis adipose mass (EAM)/body weight ratio of mice ($n = 10$).
11 Mice were fasted for 12 h before total plasma cholesterol (CHO), triglycerides (TG),
12 high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol
13 (LDL-C) levels were measured. $n = 10$. (E) Quantitative analysis fluorescence
14 intensities of YAP co-localization with PPM1B in Fig. 2D ($n = 5$). (F) Quantitative
15 analysis fluorescence intensities of p-Smad2 in cross-sections of mouse aorta of Fig.
16 2E ($n = 5$). (G) Quantitative analysis of total YAP protein , p-Smad2(ser465/467) and
17 p-Smad3(ser423/425) protein levels in the aortic tunica media of mice ($n = 5$). (H)
18 Immunofluorescence staining of YAP (red), α -SMA (green) and DAPI (blue) in cross-
19 sections of mouse aorta ($n = 5$). Scale bars: 20 μ m. Quantitative analysis of YAP in
20 cross-sections of mouse aorta based on immunofluorescence staining ($n = 5$).

21

22

